Radiopharmaceutical developers Actithera and Nuclidium have attracted significant venture capital investments to advance clinical and manufacturing capabilities. Actithera closed a $75.5 million Series A funding round to support early clinical development of its fibroblast activation protein-targeted candidate. Nuclidium finalized a CHF79 million (approximately $99.3 million) Series B round, positioning itself to overcome persistent production and supply challenges in radiopharmaceutical access by expanding global manufacturing of copper isotopes. The capital influx signals investor interest in innovative radiopharma technologies amid ongoing supply chain complexities.